TEM:NSD-Tempus AI, Inc. Class A Common Stock (USD)

COMMON STOCK | Health Information Services |

Last Closing

USD 34.39

Change

0.00 (0.00)%

Market Cap

N/A

Volume

1.09M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-04 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
GEHC GE HealthCare Technologies Inc..

N/A

USD 35.57B
HQY HealthEquity Inc

N/A

USD 7.50B
RCM R1 RCM Inc

N/A

USD 5.29B
GDRX Goodrx Holdings Inc

N/A

USD 2.93B
PGNY Progyny Inc

N/A

USD 2.70B
TXG 10X Genomics Inc

N/A

USD 2.26B
CERT Certara Inc

N/A

USD 2.23B
PRVA Privia Health Group Inc

N/A

USD 2.04B
PINC Premier Inc

N/A

USD 1.96B
BTSG BrightSpring Health Services I..

N/A

USD 1.91B

ETFs Containing TEM

REMX VanEck Rare Earth/Strateg.. 4.81 % 0.59 %

N/A

USD 0.28B
SPXZ 1.50 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector